Steatohepatitis
Lead NASH contender falls short for FDA: Could NAFLD name change shift the status quo?
In the race for a first-to-market therapy for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, there have been multiple hopeful contenders; however, none have yet crossed the FDA finish line.
No difference between semaglutide, placebo in fibrosis improvement in patients with NASH
Although semaglutide did not “significantly improve” fibrosis in patients with nonalcoholic steatohepatitis and compensated cirrhosis, notable improvements were reported in cardiometabolic parameters and markers of liver fat and injury.
Risk stratification may improve NAFLD intervention in obese, overweight populations
Results from a meta-analysis underscored the need to improve understanding of nonalcoholic fatty liver disease burden and management in at-risk individuals who are overweight and obese.
VIDEO: Women with NASH-cirrhosis at higher risk for polypharmacy to manage chronic pain
WASHINGTON — In a Healio video exclusive, Leen Al-Sayyed, MD, gastroenterology and transplant hepatology fellow at St. Louis University, reported women with nonalcoholic steatohepatitis-cirrhosis had an increased prevalence for polypharmacy.
PLX065 reduces liver fat content, prevents worsening of fibrosis in NASH
WASHINGTON — PXL065, a novel PPAR gamma-sparing chemical entity of pioglitazone, reduced liver fat content with no dose-dependent effect on weight gain in patients with nonalcoholic steatohepatitis, according to late-breaking data.
VIDEO: Terns Pharma ‘builds upon pipeline’ of NASH, obesity research
In a Healio video exclusive, Diana Chung, chief development officer at Terns Pharmaceuticals, highlights data on TERN-501, a thyroid hormone receptor beta-agonist for patients with nonalcoholic steatohepatitis.
HIV an independent risk factor for nonalcoholic steatohepatitis
A study of more than 1,300 women demonstrated that HIV is an independent risk factor for nonalcoholic steatohepatitis with significant nonalcoholic fatty liver disease activity and fibrosis, researchers reported.
AHA: Addressing ‘undiagnosed’ NAFLD could mitigate CVD risk
Nonalcoholic fatty liver disease remains widely undiagnosed, yet early identification and treatment could mitigate long-term risk for CVD, according to a new American Heart Association scientific statement.
Six recent reports from the Digital NAFLD Summit 2021
Pioglitazone safe, effective in NASH treatment
Pioglitazone was safe and effective in improving liver histology among patients with nonalcoholic steatohepatitis, according to a presenter at the Digital NAFLD Summit 2021.